The Antiviral Activities of Human Interferons
人干扰素的抗病毒活性
基本信息
- 批准号:7964667
- 负责人:
- 金额:$ 41.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AftercareAntiviral AgentsAntiviral ResponseB-LymphocytesBinding SitesBiological AssayBiological ProcessBurkitt LymphomaCell LineCellsCo-ImmunoprecipitationsComplexDengueDengue VirusDiseaseFlavivirusGene ExpressionGene Expression Microarray AnalysisGene ProteinsGenesGrowthHumanHuman ActivitiesHybridsInfectionInterferon ActivationInterferon Alfa-2aInterferon Alfa-2bInterferon Alfa-2cInterferon Type IInterferon Type IIInterferon-alphaInterferonsKnowledgeLaboratoriesMediatingMusPlayPropertyProtein FamilyProteinsRNA InterferenceResistanceReverse Transcriptase Polymerase Chain ReactionRoleSamplingSignal TransductionSuspension substanceSuspensionsSystemTestingTimeVirusVirus ReplicationWestern BlottingWorkautocrinebasedesigngene inductionin vivointerestinterferon-stimulated gene factor 3neutralizing antibodyprotein functionresearch studyresponsetranscription factortrend
项目摘要
In summary, an MTT assay was developed for suspension cells in which we can test IFN antiproliferative as well as antiviral activities at the same time. Based on results from the above mentioned assay, we were able to perform treatment on Daudi cells under conditions of non-growth inhibition but antiviral protection, and non-antiviral protection. The analysis of samples after this treatment allowed us to more precisely identify genes associated with IFN-alpha antiviral activity. Based on microarray results there were 26 genes that are commonly and significantly different between an IFN concentration leading to AV protection versus a concentration not causing AV protection. Results from antiviral neutralizing experiments suggested the association of the identified genes and proteins with IFN AV activity. Thus, this work not only represents an example of how precise results from biological assays can help in the design of experiments leading to identification of functional genes and proteins to elucidate the IFN AV effect, but this is also to our knowledge the first study involving an analysis of AV associated genes on a B cell line.
With respect to the ISGF3 complex and IFN-gamma signaling, western blot analysis revealed that phosphorylated Stat1 (Y701, as a surrogate for IFN activation) peaked at 2h when treated with IFN-alpha, remaining at low levels for up to 48h. Cells treated with IFN-gamma showed the same trend until 15h, when an increase in pStat1 was detected by an additional signaling peak that continued through 24h. Gene expression microarray analysis following IFN-gamma treatment for 24h indicated increased levels of antiviral proteins normally associated with a type-1 IFN response, such as Mx1, PKR, and OAS1. Induction of these genes by autocrine type-I and type-III IFN signaling was ruled out using both neutralizing antibodies in biological assays and by qRT-PCR. Despite the absence of any other IFNs, the ISGF3 transcription factor complex was isolated by co-immunoprecipitation after IFN-gamma treatment for 24h. It is possible that induction of this transcription factor complex plays a role in transcribing antiviral genes and the subsequent protection from viruses mediated by IFN-gamma.
总而言之,为悬浮细胞开发了MTT测定法,我们可以同时测试IFN抗增殖和抗病毒活性。根据上述测定的结果,我们能够在不增长抑制但抗病毒保护和非抗病毒保护条件下对Daudi细胞进行治疗。对这种处理后的样品的分析使我们可以更精确地识别与IFN-Alpha抗病毒活性相关的基因。基于微阵列结果,有26个基因在导致AV保护的IFN浓度之间通常且显着差异,而不是引起AV保护的浓度。抗病毒中和实验的结果表明,已鉴定的基因和蛋白质与IFN AV活性的关联。因此,这项工作不仅代表了生物测定结果如何精确导致的一个例子,可以帮助设计实验的设计,从而鉴定功能基因和蛋白质以阐明IFN AV效应,但据我们所知,这也是第一个研究,涉及对B细胞系上AV相关基因的分析。
关于ISGF3复合物和IFN-GAMMA信号传导,Western印迹分析表明,用IFN-Alpha处理磷酸化的STAT1(Y701,作为IFN激活的替代物)在2H处达到峰值,保持低水平的水平最高为48h。 用IFN-GAMMA处理的细胞直到15H都显示出相同的趋势,当时PSTAT1的增加通过持续到24小时的额外信号传导峰的增加。 IFN-GAMMA处理后24小时后,基因表达微阵列分析表明,通常与1型IFN反应相关的抗病毒蛋白水平增加,例如MX1,PKR和OAS1。 使用生物学测定中的中和抗体和QRT-PCR排除了Autocrine-I型和III型IFN信号传导诱导这些基因。 尽管没有任何其他IFN,但在IFN-GAMMA处理后,通过共免疫沉淀分离ISGF3转录因子复合物24小时。 该转录因子复合物的诱导可能在转录抗病毒基因和随后对IFN-GAMMA介导的病毒的保护作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathryn Zoon其他文献
Kathryn Zoon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathryn Zoon', 18)}}的其他基金
Novel Human Interferons Produced by Protein Engineering
蛋白质工程生产的新型人类干扰素
- 批准号:
8336183 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
Novel Human Interferons Produced by Protein Engineering
蛋白质工程生产的新型人类干扰素
- 批准号:
8156962 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
Infectious Diseases and Allergy Scientific Education and Outreach
传染病和过敏科学教育和推广
- 批准号:
8556192 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
Infectious Diseases and Allergy Scientific Education and Outreach
传染病和过敏科学教育和推广
- 批准号:
7732697 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
Activation, Maintenance and Certification of Infectious Diseases Labs
传染病实验室的激活、维护和认证
- 批准号:
8556191 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
Infectious Diseases and Allergy Scientific Education and Outreach
传染病和过敏科学教育和推广
- 批准号:
8745810 - 财政年份:
- 资助金额:
$ 41.55万 - 项目类别:
相似国自然基金
核苷类抗病毒药物嵌合型核酸纳米载体的构筑及其抗病毒性能研究
- 批准号:52303174
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向病毒核衣壳蛋白质相分离的抗病毒药物发现及机制研究
- 批准号:82302491
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
水环境中抗病毒药物及其转化副产物的识别及生态毒性效应研究
- 批准号:52300245
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
猴痘病毒入侵融合复合物、DNA聚合酶复合物的结构解析以及抗病毒药物的开发
- 批准号:82241081
- 批准年份:2022
- 资助金额:65.00 万元
- 项目类别:专项项目
CCHFV的致病机理及抗病毒药物研究
- 批准号:U22A20336
- 批准年份:2022
- 资助金额:255.00 万元
- 项目类别:联合基金项目
相似海外基金
First-in-human study of a potent anti-HBsAg neutralizing antibody
强效抗 HBsAg 中和抗体的首次人体研究
- 批准号:
10550458 - 财政年份:2023
- 资助金额:
$ 41.55万 - 项目类别:
Antiviral treatment of BK polyomavirus reactivation
BK 多瘤病毒再激活的抗病毒治疗
- 批准号:
10730924 - 财政年份:2023
- 资助金额:
$ 41.55万 - 项目类别:
Treatment of Inflammatory Complications of Viral Pneumonia
病毒性肺炎炎症并发症的治疗
- 批准号:
10383991 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes
HSV-1 编码的 MicroRNA 在眼疱疹发病机制和治疗中的作用
- 批准号:
10569577 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别: